NCT04853199: QUERCOV

Quercetin In The Treatment Of SARS-COV 2

Completed EARLY_PHASE1 Last updated 6 July 2023

What this trial tests

EARLY_PHASE1 trial testing Quercetin in SARS (Severe Acute Respiratory Syndrome) in 200 participants. Completed in 30 August 2021.

Timeline

1 June 2021

Primary endpoint
30 July 2021

30 August 2021

Quick facts

Lead sponsor	Hôpital Universitaire Sahloul
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	200
Start date	1 June 2021
Primary completion	30 July 2021
Estimated completion	30 August 2021
Sites	2 locations across Tunisia

Drugs / interventions tested

• Quercetin (QUERCETIN) — full drug profile →
• Placebo

Conditions studied

• SARS (Severe Acute Respiratory Syndrome) — all drugs for SARS (Severe Acute Respiratory Syndrome) →

Sponsor

Hôpital Universitaire Sahloul — full company profile →

Who can join

18 and older, any sex, with SARS (Severe Acute Respiratory Syndrome). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins.

Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America.

Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
   Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
2. Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review.
   Kaul R, Paul P, Kumar S, Büsselberg D, et al · · 2021 · cited 61× · PMID 34681727 · DOI 10.3390/ijms222011069
3. The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature.
   Imran M, Thabet HK, Alaqel SI, Alzahrani AR, et al · · 2022 · cited 45× · PMID 35624740 · DOI 10.3390/antiox11050876
4. Potential Benefits of Black Chokeberry (<i>Aronia melanocarpa</i>) Fruits and Their Constituents in Improving Human Health.
   Ren Y, Frank T, Meyer G, Lei J, et al · · 2022 · cited 42× · PMID 36431924 · DOI 10.3390/molecules27227823
5. Chronic HIV Infection and Aging: Application of a Geroscience-Guided Approach.
   Masters MC, Landay AL, Robbins PD, Tchkonia T, et al · · 2022 · cited 21× · PMID 35015744 · DOI 10.1097/qai.0000000000002858
6. Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19.
   Bernini R, Velotti F. · · 2021 · cited 20× · PMID 34641348 · DOI 10.3390/molecules26195803
7. Fighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now.
   Mohammed MA. · · 2023 · cited 15× · PMID 37124230 · DOI 10.3389/fphar.2023.1111329
8. Expanding Arsenal against Neurodegenerative Diseases Using Quercetin Based Nanoformulations: Breakthroughs and Bottlenecks.
   Vishwas S, Kumar R, Khursheed R, Ramanunny AK, et al · · 2023 · cited 15× · PMID 35950245 · DOI 10.2174/1570159x20666220810105421